SUPERNUS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Debt Securities, Available-for-sale of $321.82 million as of 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2022-05-12
- 2022-03-31: Debt Securities, Available-for-sale $321.82M.
- 2021-12-31: Debt Securities, Available-for-sale $255.41M.
- 2021-09-30: Debt Securities, Available-for-sale $634.05M.
- 2021-06-30: Debt Securities, Available-for-sale $631.54M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2022-03-31 | $321.82M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $255.41M 10-Q · filed 2022-05-12 |
| 2021-09-30 | $634.05M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $631.54M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $552.02M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $484.25M 10-K · filed 2022-04-13 |
| 2020-09-30 | $535.84M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $522.51M 10-Q · filed 2020-08-17 |
| 2020-03-31 | $709.82M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $757.47M 10-K · filed 2021-03-08 |
| 2019-09-30 | $776.25M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $764.98M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $692.72M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $582.57M 10-K · filed 2020-02-28 |
| 2018-09-30 | $616.71M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $642.52M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $220.65M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $173.37M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |